drugset / Trial / NCT07469306
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
Timeline
- Start
- 2026-08-10
- Primary completion
- 2027-08-10
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 825 mg/m2 | — |
| Comparator | Capecitabine | Small molecule | 1000 unknown | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Comparator | Tislelizumab | Monoclonal antibody | 200 mg | — |
Indications
No indication recorded.